Rankings
▼
Calendar
NVAX Q2 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$415M
-2.1% YoY
Gross Profit
$369M
88.9% margin
Operating Income
$161M
38.7% margin
Net Income
$162M
39.1% margin
EPS (Diluted)
$0.99
QoQ Revenue Growth
+342.7%
Cash Flow
Operating Cash Flow
$314M
Free Cash Flow
$311M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$1.8B
Total Liabilities
$2.3B
Stockholders' Equity
-$432M
Cash & Equivalents
$680M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$415M
$424M
-2.1%
Gross Profit
$369M
$369M
+0.2%
Operating Income
$161M
$55M
+190.3%
Net Income
$162M
$58M
+179.9%
Revenue Segments
Royalties and Other
$396M
95%
Product
$20M
5%
Geographic Segments
Rest of the World
$18M
91%
North America
$2M
8%
Europe
$169,000
1%
← FY 2024
All Quarters
Q3 2024 →